Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc (GSK) covers the period ending February 2015. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMR), or connected persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share transaction details rather than comprehensive financial performance.
Material Changes
The filing reports an increase in the notional allocation of GSK American Depositary Shares (ADSs) on January 30, 2015. This increase resulted from the revaluation of the cash element of the notional investment held within the GSK 401K plan at a price of $44.00 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific transaction notification.
Important Facts for Investors
- Transaction Date: January 30, 2015 (notified February 2, 2015).
- Transaction Type: Increase in notional allocation of ADSs within the GSK 401K plan.
- Price: $44.00 per ADS.
- Director Involved: Dr M M Slaoui received an allocation of 20 ADSs.
- Connected Person Involved: Dr K Slaoui (connected to Dr M M Slaoui) received an allocation of 5 ADSs.